Nexvet Biopharma plc (NASDAQ:NVET) was down 6.6% on Tuesday . The company traded as low as $5.00 and last traded at $5.09, with a volume of 59,863 shares trading hands. The stock had previously closed at $5.45.

A number of equities research analysts recently weighed in on NVET shares. Zacks Investment Research raised shares of Nexvet Biopharma plc from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Credit Suisse Group AG reissued a “buy” rating on shares of Nexvet Biopharma plc in a research report on Saturday, May 14th.

The firm’s market capitalization is $61.75 million. The company’s 50 day moving average price is $5.05 and its 200 day moving average price is $3.70.

Nexvet Biopharma plc (NASDAQ:NVET) last issued its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by $0.06. Equities analysts anticipate that Nexvet Biopharma plc will post ($1.82) EPS for the current fiscal year.

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.